Collaboration combines Illumina's sequencing
technologies and Illumina Connected Software with NVIDIA tools to
develop biological foundation models
SAN
DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and
analysis, today announced it is collaborating with NVIDIA to
advance technology platforms for the analysis and interpretation of
multiomic data, accelerating progress in clinical research,
genomics AI development, and drug discovery.
To optimize analysis of the vast amounts of data involved in
multiomic research, Illumina and NVIDIA will combine advancements
in AI with multiomic data at scale. Leveraging Illumina's leading
sequencing technology and informatics tools alongside NVIDIA's
leading AI technology, the partnership aims to accelerate drug
discovery and clinical development, delivering powerful tools to
help pharmaceutical companies identify new and better drug
targets.
Illumina's leading sequencing technology—as well as its menu of
DRAGEN-powered multiomics offerings, genomics AI tools, and
Illumina Connected Analytics platform—has streamlined genomic data
generation and analysis. Illumina has invested in AI for genomic
interpretation, developing the leading SpliceAI, PrimateAI-3D, and
Emedgene xAI algorithms.
Now, in addition to its own efforts, Illumina will look to
expand its customer offerings with models developed by the NVIDIA
Biology Foundation Model Research Team and partners. Customers will
also be able to leverage these models with their own proprietary
datasets to improve the performance for biologically relevant tasks
of interest, such as cell state or gene transcription
prediction.
With this new partnership, the global R&D community can tap
into rich genomic data by integrating NVIDIA RAPIDS™
accelerated data science software with the NVIDIA
BioNeMo™ platform's generative AI models and fine-tuning
capabilities for proprietary datasets, as well as MONAI for spatial
cell imaging workflows. Illumina and NVIDIA will work to make these
tools accessible on the Illumina Connected Analytics platform.
"Over the past 20 years, Illumina has democratized sequencing,
and with the progress in AI and multiomic analysis, we are enabling
customers to derive novel insights for their applications," said
Rami Mehio, head of global software
and informatics at Illumina. "This collaboration with NVIDIA moves
us closer to that vision. This is also part of our commitment to
continue to enrich our analysis and interpretation tools that will
enable deeper biological insights, delivering total workflow
solutions for our customers."
"AI and data science will find their most profound application
in genomics," said Rory Kelleher,
senior director, global head of Business Development, Healthcare
and Life Sciences at NVIDIA. "Combining Illumina's world-leading
sequencing and analytics platforms with NVIDIA's accelerated
computing and AI, we will drive the next generation of genomics
interpretation and democratize genomics for drug discovery through
AI-powered insights."
In the first phase of the collaboration, Illumina and NVIDIA
will work toward enabling DRAGEN algorithms on NVIDIA GPUs.
Bringing Illumina DRAGEN to NVIDIA accelerated computing will
expand the accessibility of Illumina multiomics analysis. The two
companies will also work to incorporate NVIDIA's image processing
and single-cell tertiary analysis tools onto the Illumina Connected
Software multiomics module.
Use of forward-looking statements
This release may contain forward-looking statements that involve
risks and uncertainties. Among the important factors to which our
business is subject that could cause actual results to differ
materially from those in any forward-looking statements are: (i)
challenges inherent in developing and launching new products and
services, including modifying and scaling manufacturing operations,
and reliance on third-party suppliers for critical components; (ii)
our ability to manufacture robust instrumentation and consumables;
and (iii) the acceptance by customers of our newly launched
products, which may or may not meet our and their expectations,
together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts' expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X, Facebook,
LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli
Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original
content:https://www.prnewswire.com/news-releases/illumina-and-nvidia-collaborate-to-decode-biology-and-propel-precision-health-302348920.html
SOURCE Illumina, Inc.